NCT05627960View on ClinicalTrials.gov

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
Triple Negative Breast CancerHormone-Resistant Breast CancerNon Small Cell Lung CancerMesothelioma
Interventions
DRUG

AG-01 Compound

"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."

Trial Locations (1)

21201

RECRUITING

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

Sponsors
All Listed Sponsors
collaborator

University of Maryland Greenebaum Cancer Center

OTHER

lead

A&G Pharmaceutical Inc.

INDUSTRY